ADVA
20.12.2019 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 150-XG480 has become the first 100Gbit/s solution on the market to achieve MEF 3.0 Carrier Ethernet certification. The compact metro edge device is now the industry’s only 100Gbit/s packet aggregation and demarcation technology proven to offer the highest available levels of performance, assurance and agility. With the ADVA FSP 150-XG480, enterprises and communication service providers (CSPs) can address the boom in cloud computing and mobile services by smoothly transitioning to 10 and 25Gbit/s service aggregation. What’s more, ADVA’s MEF 3.0-compliant technology enables them to meet the need for high-capacity wholesale, mobile and business services with a solution that supports automated networking and 5G-ready architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005017/en/
“CSPs now have the power to tackle the demand for 100Gbit/s aggregation at the metro edge with a solution guaranteed to deliver the highest industry standards for performance and assurance. With our unique technology, there’s now a simple and extremely cost-efficient route to MEF 3.0-certified 100Gbit/s service aggregation,” said James Buchanan, GM, Edge Cloud, ADVA. “Higher speeds in the access network are becoming essential. In fact, with the emergence of more and more connected devices as well as the unprecedented surge in video streaming platforms, 10Gbit/s is becoming the new 1Gbit/s. What our FSP 150-XG480 offers is a future-proof way to deliver MEF CE services up to 100Gbit/s and enable the efficient and reliable aggregation of multiple 10Gbit/s streams.”
The compact and powerful ADVA FSP 150-XG480 aggregator with high-density 1, 10 and 25Gbit/s port count is the ultimate tool for fighting bandwidth bottlenecks and evolving metro networks to 100Gbit/s. Its MEF 3.0-compliant interfaces and operation and management capabilities enable seamless integration into existing networks and established processes. The ADVA FSP 150-XG480 offers a range of advantages for connectivity and synchronization in mobile backhaul networks. These include leveraging ADVA’s Oscilloquartz Syncjack™ technology to constantly control the accuracy of network timing. It’s also the only device available with 100Gbit/s line-rate service activation and testing, so there’s no need for CSPs to compromise on high-value SLA-based business services.
“Achieving MEF 3.0-compliant status with our FSP 150-XG480 highlights the leading role ADVA continues to play in the Carrier Ethernet space. This certification is also great news for enterprises across the world as well as mobile network operators looking to meet soaring data demand. Now they can map 10 and 25GbE into 100Gbit/s aggregated bandwidth with a solution that easily expands to meet the coming requirements of 5G networks,” commented Eli Angel, VP, product line management, Ethernet access, ADVA. “Our FSP 150-XG480 is the key to future scalability. It also features an incredibly small form factor and environmentally hardened design, delivering a significant cost advantage over competing technology.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005017/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom